Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML) - MPR
Links shared publicly online about this topic.
- 670total visits
Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML) - MPR
empr.com —
Celator Pharmaceuticals announced results from its Phase 2 trial of CPX-351 (cytarabine and daunorubicin) Liposome Injection for the treatment of adult patients with acute myeloid leukemia (AML).
View full resource at empr.com
Tags: Leukemia, Acute Myelogenous Leukemia, Pharma, Phase 2 Clinical Trial, News
Most Recently Shared on December 8, 2010 at 6:26 pm By:
MPR News: Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML): Celator Pharmaceuticals an... http://bit.ly/ejZDj3
Advertisement
